References
- Dahl SG, Sylte I. From genomics to drug targets. J. Psychopharmacol.20(Suppl. 4), 95–99 (2006).
- Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat. Rev. Genet.5, 7–13 (2004).
- Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet.937–947 (2004).
- Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J. Psychopharmacol.20(Suppl. 4), 85–94 (2006).
- Kroeze WK, Roth BL. Screening the receptorome. J. Psychopharmacol.20(Suppl. 4), 41–46 (2006).
- Hopkins MM, Ibarreta D, Gaisser S et al. Putting pharmacogenetics into practice. Nat. Biotechnol.24(4), 403–410 (2006).
- Gurwitz D, Lunshof JE, Altman RB. A call for the creation of personalized medicine databases. Nat. Rev. Drug Discov.23–26 (2006).
- Kirchheiner J, Gründemann D, Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J. Psychopharmacol.20(Suppl. 4), 27–32 (2006).
- Jarnagin K. ID and validation of biomarkers. Genetic Engineering News6–7 (2006).
- Lunshof JE, Pirohamed M, Gurwitz D. Personalized medicine: decades away? Pharmacogenomics7(2), 237–241 (2006).
Websites
- Kalorama Information. Molecular diagnostics for pharmacogenetic testing: testing volume, cost per test, and market potential www.kaloramainformation.com/
- Martin PA, Lewis G, Smart A, Webster A. False positive? Prospects for the clinical and commercial development of pharmacogenetics. University of Nottingham/University of York www.nottingham.ac.uk/pgx
- Institute for Prospective Technological Studies. Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. European Commission www.jrc.es/home/pages/detail. cfm?prs=1387
- The Royal Society Personalised medicines: hopes and realities, London www.royalsoc.ac.uk/displaypagedoc.asp? id=15874
- UK Pharmacogenetics Study Group. Policy issues in pharmacogenetics. www.york.ac.uk/res/pgx/publications